Your browser is no longer supported. Please, upgrade your browser.
EXEL Exelixis, Inc. daily Stock Chart
Exelixis, Inc.
Index- P/E- EPS (ttm)-0.84 Insider Own0.60% Shs Outstand233.91M Perf Week-5.88%
Market Cap2.54B Forward P/E- EPS next Y-0.03 Insider Trans-7.48% Shs Float204.72M Perf Month-11.40%
Income-189.60M PEG- EPS next Q-0.13 Inst Own82.20% Short Float9.98% Perf Quarter17.37%
Sales71.50M P/S35.59 EPS this Y41.30% Inst Trans-1.43% Short Ratio3.15 Perf Half Y125.73%
Book/sh-0.81 P/B- EPS next Y86.90% ROA-45.50% Target Price18.00 Perf Year85.03%
Cash/sh1.40 P/C7.76 EPS next 5Y- ROE145.60% 52W Range3.55 - 15.58 Perf YTD92.91%
Dividend- P/FCF43.88 EPS past 5Y0.90% ROI-43.80% 52W High-30.17% Beta1.62
Dividend %- Quick Ratio1.80 Sales past 5Y-27.50% Gross Margin93.40% 52W Low206.48% ATR0.72
Employees115 Current Ratio1.80 Sales Q/Q353.70% Oper. Margin- RSI (14)36.48 Volatility4.85% 6.08%
OptionableYes Debt/Eq- EPS Q/Q27.00% Profit Margin- Rel Volume0.56 Prev Close10.92
ShortableYes LT Debt/Eq- EarningsOct 28 AMC Payout- Avg Volume6.48M Price10.88
Recom1.40 SMA20-9.47% SMA50-11.65% SMA20044.36% Volume3,652,522 Change-0.37%
Oct-10-16Upgrade Piper Jaffray Neutral → Overweight
Sep-15-16Reiterated Stifel Buy $12 → $15
Aug-04-16Reiterated Stifel Buy $10 → $12
Jun-21-16Reiterated Leerink Partners Outperform $8 → $10
Apr-26-16Reiterated Stifel Buy $7 → $8
Apr-04-16Upgrade Stifel Hold → Buy $7
Jan-19-16Upgrade Leerink Partners Mkt Perform → Outperform
Sep-02-14Downgrade Stifel Buy → Hold
Feb-07-14Reiterated Stifel Buy $9 → $11
Jan-21-14Reiterated Maxim Group Buy $7.50 → $11
Nov-12-13Upgrade Maxim Group Hold → Buy $7.50
May-28-13Downgrade Maxim Group Buy → Hold $35 → $35
Nov-30-12Reiterated Stifel Nicolaus Buy $8 → $9
Apr-20-12Initiated Maxim Group Buy $9
Mar-15-12Resumed Stifel Nicolaus Buy $8
Aug-17-11Initiated Stifel Nicolaus Hold $8
Nov-18-09Downgrade Merriman Buy → Neutral
Jun-17-09Initiated Boenning & Scattergood Neutral
Dec-15-08Reiterated Lazard Capital Buy $7 → $8
Nov-24-08Reiterated Lazard Capital Buy $7
Oct-28-16 11:23AM  AbbVie (ABBV) Q3 Earnings in Line, Revenues Lag Estimates
09:35AM  Sarepta Therapeutics (SRPT) Incurs Narrower Y/Y Loss in Q3
08:24AM  McKesson (MCK) Misses on Q2 Earnings & Sales, Cuts View
Oct-27-16 11:45AM  Celgene (CELG) Beats on Q3 Earnings, Raises '16 Outlook
10:33AM  The Medicines Co. (MDCO) Q3 Loss Narrower than Expected
Oct-26-16 09:30AM featured highlights: Incyte, LegacyTexas Financial Group, Exelixis, Bayerische Motoren Werke Aktiengesellschaft and EQT Midstream Partners
09:17AM  Express Scripts (ESRX) Q3 Earnings in Line, Revenues Lag
Oct-25-16 04:32PM  Ligand Partner Melinta Therapeutics Submits NDA for Baxdela
10:04AM  Merck (MRK) Beats on Q3 Earnings & Revenues, Lifts View
09:48AM  5 Profitable Stocks for Outstanding Returns
09:27AM  Aduro Stock Down on Partial Clinical Hold on LADD Studies
07:54AM  What's in Store for Merit Medical (MMSI) in Q3 Earnings?
Oct-24-16 04:19PM  C.R. Bard (BCR) to Report Q3 Earnings: What's in the Cards?
11:04AM  Can Nutrisystem (NTRI) Surprise Investors in Q3 Earnings?
09:35AM  Merck Gets FDA Approval for Investigational Drug Zinplava
Oct-21-16 10:00AM  Amgen's (AMGN) Xgeva Meets Endpoint in Phase III Study
Oct-20-16 04:21PM  Exelixis to Release Third Quarter 2016 Financial Results on Thursday, November 3, 2016 Business Wire
03:52PM  41 Billion Reasons Why Gilead Sciences Might Need New Management at Motley Fool
09:58AM  Merck's Antiviral Medicine Meets Endpoint in Phase III
07:51AM  Eli Lilly Lartruvo Gets FDA Approval for Soft Tissue Sarcoma
Oct-19-16 09:56AM  AstraZeneca's Hyperkalemia Drug NDA Resubmission Accepted
07:55AM  Shire Cancer Drug Onivyde Receives EU Marketing Approval
Oct-18-16 10:05AM  J&J (JNJ) Outshines in Q3 Earnings on Strong Pharma Sales
09:23AM  Teva Trisenox Wins CHMP Nod for Expanded Use in Leukemia
09:23AM  Biotech Review DVAX Vaccine Faces Crucial PDUFA Date, CLDX Seeks Fast-Track Orphan Drug Status CNW Group
08:59AM  PTC Therapeutics Falls on FDA Denial of DMD Drug Appeal
Oct-17-16 09:14AM  Allergan (AGN) Gains Rights to RTGel from UroGen Pharma
08:57AM  Allergan's Belkyra Gets Swedish Approval for Double Chin
08:36AM  Pfizer and Bristol-Myers Squibb Could Face a Big Threat from Small Biotech Exelixis at Motley Fool
Oct-14-16 10:03AM  Sunesis Submits Response to Questions on Leukemia Drug
09:59AM  OncoGenex Cancer Drug Fails in Phase III Study, Stock Down
Oct-13-16 05:00PM  Exelixis Goes for It at Motley Fool
02:25PM  Supernus (SUPN) Reports Encouraging Data from ADHD Study
09:59AM  AMAG Issues Encouraging Updates on Makena & Feraheme
09:46AM  Will These 5 Drug Stocks Be Big Winners This Earnings Season?
08:28AM  Exelixis, Inc. breached its 50 day moving average in a Bearish Manner : EXEL-US : October 13, 2016
Oct-11-16 04:30PM  These 3 Little Biotechs Just Scored Big at Motley Fool
01:25PM  Pfizer's Kidney Drug Faces a New Rival (EXEL, PFE) at Investopedia
Oct-10-16 08:41PM  Exelixis Finds Success with Cabozantinib (EXEL) at Investopedia
11:47AM  Deere & Company (DE), Gas Natural Inc. (EGAS) & More: Why These Stocks are Trending Today at Insider Monkey
11:43AM  Traders bet Exelixis will hold gains
10:12AM  Stocks to Watch: Mylan, Twitter, Dover at The Wall Street Journal
09:10AM  Exelixis upgraded by Piper Jaffray
08:40AM  Exelixis Continues Massive Run With Positive Cabosun Results at 24/7 Wall St.
03:32AM  Exelixis and Pfizer drugs compete in kidney cancer trial
02:15AM  Exelixis and Pfizer drugs face off in kidney cancer
02:15AM  Exelixis Announces Positive Results from Phase 2 CABOSUN Trial of Cabozantinib Versus Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma Presented at ESMO 2016 Business Wire
Oct-08-16 09:12PM  Better Buy: Exelixis, Inc. vs. Roche at Motley Fool
Oct-07-16 01:38PM  Exelixis Reports Genitourinary Results (EXEL) at Investopedia
12:56PM  These 2 Big Catalysts Pushed Exelixis, Inc. Higher By 15% in September at Motley Fool
04:01AM  Exelixis Announces Genentech Presentation of Preliminary Phase 1b Results for the Combination of Cobimetinib, Vemurafenib and Atezolizumab at ESMO 2016 Congress Business Wire
04:00AM  Exelixis Announces Phase 1 Trial Results for Cabozantinib in Combination with Nivolumab in Advanced Genitourinary Tumors Business Wire
Oct-04-16 09:15AM  Key FDA Decisions and Trial Results Expected in October at 24/7 Wall St.
08:56AM  Forget Celldex Therapeutics, Inc.: These 2 Stocks Doubled Last Year at Motley Fool
Oct-03-16 04:05PM  Exelixis and Ipsen to Host Investor and Media Briefing to Discuss Data Presented at the ESMO 2016 Congress Business Wire
Sep-30-16 10:55AM  Piecing your biotech together again BioFlash podcast at
08:45AM  Call buyers looking for more in Exelixis
Sep-29-16 05:20PM  Why Exelixis, Inc. Continued Its Downfall Today at Motley Fool -8.01%
04:21PM  Why Exelixis, Inc. Got Hammered Today at Motley Fool
Sep-28-16 04:48PM  Why Exelixis, Inc. Got Hammered Today at Motley Fool -13.76%
02:21PM  Exelixis (EXEL) Stock Plummets on Cancer Drug Trial Results, Leerink: Selloff Overdone
Sep-26-16 04:36PM  EXELIXIS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
10:15AM  4 Biopharma Companies Moving on Monday Ahead of the Presidential Debate at 24/7 Wall St.
08:33AM  Surging Earnings Estimates Signal Good News for Exelixis (EXEL)
06:02AM  Exelixis Elects Julie Anne Smith to Its Board of Directors Business Wire
06:00AM  Exelixis Announces Collaborator Daiichi Sankyos Initiation of Phase 3 Clinical Development for CS-3150, a Selective Mineralocorticoid Receptor Antagonist Business Wire
Sep-22-16 06:50PM  Cramer: I overstayed my welcome on this stock at CNBC
Sep-20-16 04:55PM  Exelixis Provides Update on Timing of Key Cabozantinib Clinical Data Presentation at the ESMO 2016 Congress Business Wire
11:59AM  2 Bullish Stock Picks and 2 Stocks to Sell Short
08:37AM  3 Reasons Momentum Stock Investors Will Love Exelixis (EXEL)
Sep-17-16 11:13AM  These 3 Stocks Have Doubled Their Investors' Money at Motley Fool
Sep-15-16 11:11AM  Will Exelixis (EXEL) Continue to Surge Higher?
Sep-14-16 07:50PM  Exelixis Wins EU Approval for Cabometyx RCC Treatment (EXEL) at Investopedia +5.69%
04:27PM  Bevy Of Biotech Stocks Healthy; Sarepta, Bluebird, Exelixis Soar
02:05PM  Bevy Of Biotech Stocks Healthy; Sarepta, Bluebird, Exelixis Soar
10:03AM  Exelixis (EXEL) Stock Advances, EC Approves Kidney Cancer Drug
09:34AM  4 stocks to watch at MarketWatch
08:20AM  Key FDA Decisions and Trial Results Coming in the Next 2 Months at 24/7 Wall St.
01:00AM  European Commission Approves CABOMETYX (cabozantinib) Tablets for the Treatment of Advanced Renal Cell Carcinoma Following VEGF-Targeted Therapy Business Wire
Sep-13-16 11:25AM  Exelixis Shares Soar on Cancer Therapies (EXEL) at Investopedia
Sep-08-16 08:08AM  The Clear Reason Behind Exelixis, Inc.'s 21% Gain in August at Motley Fool
08:05AM  Key FDA Decisions and Trial Results Expected in October at 24/7 Wall St.
Sep-07-16 03:44PM  Exelixis Reports Interim Analysis of Liver Cancer Trial Data
12:37PM  4 stocks to watch at MarketWatch
10:40AM  ETFs with exposure to Exelixis, Inc. : September 7, 2016
Sep-06-16 05:08PM  Exelixis Announces Outcome from First Planned Interim Analysis of the Phase 3 CELESTIAL Trial of Cabozantinib in Patients with Advanced Hepatocellular Carcinoma Business Wire
Sep-03-16 02:50PM  3 Biotech Stocks to Buy in September at Motley Fool
Aug-31-16 04:17PM  Exelixis to Present at the Morgan Stanley Global Healthcare Conference on September 13 Business Wire
08:30AM  Exelixis-discovered Compounds To Be Featured in 15 Presentations at the ESMO 2016 Congress Business Wire
Aug-26-16 09:00AM  Why Exelixis (EXEL) Could Be Positioned for a Surge
Aug-25-16 09:38AM  4 stocks to watch at MarketWatch
Aug-24-16 12:39PM  Mobileye And Three More Stocks Breaking Out at Forbes -6.37%
08:30AM  Exelixis Announces Redemption of All Remaining 4.25% Convertible Senior Subordinated Notes Due 2019 Business Wire
Aug-23-16 12:07PM  4 Biotech Stock Charts You Must See
Aug-22-16 11:25AM  ETFs with exposure to Exelixis, Inc. : August 22, 2016
08:35AM  EXELIXIS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement
Aug-11-16 01:04PM  EXELIXIS, INC. Financials
12:45PM  ETFs with exposure to Exelixis, Inc. : August 11, 2016
Aug-10-16 11:19AM  Exelixis, Inc. :EXEL-US: Earnings Analysis: Q2, 2016 By the Numbers : August 10, 2016
Aug-09-16 05:26PM  EXELIXIS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities
Exelixis, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of new medicines with the potential to enhance care and outcomes for people with cancer. It focuses on advancing cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors, which has shown clinical anti-tumor activity in approximately 20 forms of cancer and is the subject of a broad clinical development program. The company has received regulatory approval for two separate formulations of cabozantinib for the treatment of certain forms of kidney and thyroid cancer and marketed as CABOMETYX tablets in the United States and COMETRIQ capsules in the United States and European Union respectively. It also offers COTELLIC (cobimetinib), a selective inhibitor of MEK, in the United States and European Union; and is being evaluated for further potential indications by Roche and Genentech under collaboration with Exelixis. Exelixis, Inc. has collaboration and license agreements with Ipsen Pharma SAS, Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Sanofi, Merck, and Daiichi Sankyo Company Limited for the development and commercialization of various compounds and programs. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Schwab GiselaPres Prod Dev & Med Aff & CMOAug 31Option Exercise9.73132,6621,290,801267,596Sep 02 04:34 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOAug 31Sale10.98131,1551,440,082136,441Sep 02 04:34 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOAug 04Option Exercise9.7342,338411,949174,354Aug 05 07:29 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOAug 04Sale11.0042,338465,718132,016Aug 05 07:29 PM
Hessekiel JeffreyEVP and General CounselJun 01Option Exercise1.70200,000340,000230,367Jun 02 06:37 PM
WILLSEY LANCEDirectorMay 11Buy4.9520,00099,000568,273May 11 05:23 PM
WILLSEY LANCEDirectorMay 09Buy4.9740,000198,900548,273May 11 05:23 PM
WILLSEY LANCEDirectorDec 11Buy4.7850,000239,000494,975Dec 11 07:43 PM
WILLSEY LANCEDirectorDec 10Buy4.9950,000249,550444,975Dec 11 07:43 PM